Wealthspire Advisors (New York)’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $392K | Buy |
881
+151
| +21% | +$67.2K | ﹤0.01% | 602 |
|
|
2025
Q1 | $354K | Sell |
730
-19
| -3% | -$9.21K | ﹤0.01% | 598 |
|
|
2024
Q4 | $302K | Sell |
749
-43
| -5% | -$17.3K | ﹤0.01% | 642 |
|
|
2024
Q3 | $368K | Buy |
792
+159
| +25% | +$73.9K | ﹤0.01% | 573 |
|
|
2024
Q2 | $297K | Sell |
633
-108
| -15% | -$50.6K | ﹤0.01% | 545 |
|
|
2024
Q1 | $310K | Sell |
741
-228
| -24% | -$95.3K | ﹤0.01% | 514 |
|
|
2023
Q4 | $394K | Buy |
969
+310
| +47% | +$126K | 0.01% | 455 |
|
|
2023
Q3 | $229K | Sell |
659
-1
| -0.2% | -$348 | ﹤0.01% | 536 |
|
|
2023
Q2 | $232K | Buy |
+660
| New | +$232K | ﹤0.01% | 498 |
|
|
2023
Q1 | – | Sell |
-833
| Closed | -$241K | – | 598 |
|
|
2022
Q4 | $241K | Buy |
+833
| New | +$241K | ﹤0.01% | 505 |
|
|
2021
Q2 | – | Sell |
-2,714
| Closed | -$583K | – | 662 |
|
|
2021
Q1 | $583K | Sell |
2,714
-88
| -3% | -$18.9K | 0.01% | 356 |
|
|
2020
Q4 | $662K | Buy |
2,802
+794
| +40% | +$188K | 0.02% | 262 |
|
|
2020
Q3 | $546K | Buy |
2,008
+117
| +6% | +$31.8K | 0.03% | 171 |
|
|
2020
Q2 | $549K | Sell |
1,891
-438
| -19% | -$127K | 0.04% | 146 |
|
|
2020
Q1 | $554K | Buy |
2,329
+1,335
| +134% | +$318K | 0.02% | 277 |
|
|
2019
Q4 | $218K | Buy |
+994
| New | +$218K | 0.02% | 191 |
|
|
2019
Q1 | – | Sell |
-220
| Closed | -$36K | – | 780 |
|
|
2018
Q4 | $36K | Buy |
+220
| New | +$36K | ﹤0.01% | 230 |
|